Kristoffer Unterbruner
Kristoffer Unterbruner is a molecular biologist and portfolio manager at Medical Strategy, a healthcare investment management firm. He is recognized for his expertise in oncology and has provided insights into BioNTech's innovative approaches to cancer treatment, particularly highlighting the potential of their bispecific antibody, BNT327, which aims to challenge existing therapies in the market.
Global Media Ratings
Countries Mentioned
No country-level mention data available.
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Switzerland:
Kristoffer Unterbruner is a molecular biologist and portfolio manager who discussed the potential of BNT327.
8